Leveraging Interim Analyses to Optimize Late Phase Clinical Trial Decision Making

Interim analyses (IA) are an essential part of clinical trials that—as a form of adaptive design—can help sponsors make informed decisions about whether to keep a trial going or discontinue it entirely. Join Rho’s Brett Gordon, Ben Vaughn, and Scott Mollan for this Q&A roundtable that will cover some of the most frequently asked questions they get from pharma companies about interim analysis. You’ll learn:

• What the different types of IAs are as well as the risks and benefits of each
• Key statistical and design considerations as well as operational expectations of IAs
• Case studies that demonstrate the potential applications of different IA options
• Best practices when presenting IA data to the FDA